Search research articles
Contact Us
Filters
Showing results (671-680 of 692) with videos related to
Page
of 70
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
JNCI Cancer Spectrum
|
July 23, 2025
Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment
P Travis Courtney, Jesus E Juarez Casillas, Eulanca Y Liu, et al.
The Lancet. Oncology
|
January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Holly Hartman, et al.
JAMA Network Open
|
December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis
Ting Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
The Lancet. Oncology
|
March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Amar U Kishan, Yilun Sun, Alison C Tree, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 9, 2020
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control
Rebecca G Levin-Epstein, Naomi Y Jiang, Xiaoyan Wang, et al.
The Lancet. Oncology
|
October 1, 2011
Delivering affordable cancer care in high-income countries
Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, et al.
Lancet (London, England)
|
March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Christopher C Parker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients
Rebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Ting Martin Ma, Yilun Sun, Shawn Malone, et al.
Page
of 70
Search research articles
Search
Showing results (671-680 of 692) with videos related to
Sort By:
Page
of 70
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
JNCI Cancer Spectrum
|
July 23, 2025
Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment
P Travis Courtney, Jesus E Juarez Casillas, Eulanca Y Liu, et al.
The Lancet. Oncology
|
January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Holly Hartman, et al.
JAMA Network Open
|
December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis
Ting Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
The Lancet. Oncology
|
March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Amar U Kishan, Yilun Sun, Alison C Tree, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 9, 2020
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control
Rebecca G Levin-Epstein, Naomi Y Jiang, Xiaoyan Wang, et al.
The Lancet. Oncology
|
October 1, 2011
Delivering affordable cancer care in high-income countries
Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, et al.
Lancet (London, England)
|
March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Christopher C Parker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients
Rebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Ting Martin Ma, Yilun Sun, Shawn Malone, et al.
Page
of 70